You are here Home R & D
Overview

Headed by a strong pool of 400+ scientists and researchers, R & D is the key growth driver for Intas. Its constant quest for developing new products and technology has led breakthrough innovations in a wide spectrum of areas such as Oncology, hormones & NDDS, apart from other generic products. Till date, Intas has filed 50+ patents on novel formulations, API polymorphs/processes & analytical methods to its credit.

Intas' continuous R & D initiatives have strengthened its product basket with delivery of niche and complex products. Intas is extensively working on Para IV and 505 (b) 2 products for USA market and few products are already filed with USFDA. Intas targets to file more than 5 Para IV applications to US market each year.

Intas Pharmaceuticals is engaged in research, development and commercialization of novel therapeutic products for the treatment of cancer, infectious diseases and acute medical emergencies. The company in collaboration with US based Jina Pharmaceuticals Inc. has developed a clinically validated proprietary Nanoaqualip™ technology to formulate drug products. The newly formulated drugs are less toxic with improved bioavailability and better therapeutics. Based on Nanoaqualip™ technology the company is enhancing broader applications of generic drugs, difficult to formulate drugs and drugs of which the patent rights are near expiration through the development of improved delivery system.

Intas is actively involved in the development and commercialization of biologics. Since inception, 8 biologics have been commercialized in India and around 15 biologics are at different stages of development. The highly qualified and capable R&D, focuses on the biosimilar product development keeping the European and the US Regulatory guidelines in the view. One of the assets is under registration with the EU authority and another at advanced stage of clinical development in the European region.

The company is also focused on discovery and development of New Chemical Entity (NCE’s) targeting cancer and neurodegenerative diseases such as bipolar disorder. The molecule has completed Phase-Ib Clinical Studies & entering into Phase-II Efficacy Studies.

Intas' R & D strategies are focused on 2 major areas:

1. Pharmaceutical Formulation Development

Intas' primary focus area in formulation development includes:

  • Day 1 launch upon patent expiry
  • New drug formulations for existing products for lifecycle management
  • Niche Formulations with technology barrier
  • Non-infringing formulations under Para-IV/ 505 b (2) categories for launch of products in US prior to the patent expiration
  • New drug delivery platforms

2. API Development

Intas' primary focus area of API development R & D team is:

  • Vertical Integration in oncology and non-oncology range of products
  • Development of non-infringing API to support FTF (first to file) & Para IV filings
  • Achieving cost efficiency through process optimization
  • Generating IPR on process chemistry